

COVID-19 Vaccine Quick Reference

The health unit continues to recommend that adults over the age of 30 receive Moderna for their booster dose, as current evidence indicates that it provides improved protection from COVID-19, including from the Omicron variant, compared to other vaccine formulations. However, those who wish to receive the Pfizer vaccine may request it at their appointment.

Below are 5 tables that outline dosing, vaccines and eligibility criteria

(Table-1) Eligible by Age and First Nations/Metis/Inuit Status for Moderna/Pfizer Vaccines

	Vaccine	Primary Series	1 st Booster (Dose 3)	2 nd Booster (Dose 4)
Ages 5 to 11 Must be 5 years of age on day of vaccination	Pfizer pediatric formulation (orange vial)	2 dose series 8 weeks (56 days)	No	No
		Minimum 21 days with informed consent Dosage: 0.2 ml		
Ages 12 to 17 To receive Pfizer only Medical contraindication to receive Moderna	Pfizer Adult/Adolescent formulation (purple vial)	2 dose series 8 weeks (56 days) Minimum 19 days with informed consent	Yes 6 months (168 days) after second dose Minimum 3 months (84 days) with informed consent	No
		Dosage: 0.3 ml	Dosage: 0.3 ml	
Ages 18 to 29 *Preferred to receive Pfizer If client requests Moderna must be informed consent	Pfizer Adult/Adolescent formulation (purple vial)	2 dose series	Yes	No ** Yes if: 18+ First Nations, Inuit, Metis and their non-Indigenous household members*
		8 weeks (56 days) Minimum 19 days with informed consent Dosage: 0.3 ml	3 months (84 days) after second dose Dosage: 0.3 ml	5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml
	Moderna **only to be used when supply of Pfizer is depleted or with client informed consent	2 dose series	Yes	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members*
		8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	3 months (84 days) after second dose Dosage: 0.25ml	5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.25ml
Novavax	2 dose series	Yes	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members*	
	8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	3 months (84 days) after second dose Dosage: 0.5 ml	5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml	

	Vaccine	Primary Series	1 st Booster (Dose 3)	2 nd Booster (Dose 4)
<p>Ages 30 to 59 Those with medical contraindications to Moderna to receive Pfizer.</p> <p>Those who wish to receive Pfizer vaccine may request it.</p> <p>Moderna booster doses provide improved protection from COVID-19, including from the Omicron variant, compared to other vaccine formulations.</p>	Pfizer Adult/Adolescent formulation	2 dose series 8 weeks (56 days) Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after second dose Dosage: 0.3 ml **Preferentially recommended to use Moderna	No <u>** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members*</u> 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml **Preferentially recommended to use Moderna
	Moderna	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.25ml	No <u>** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members*</u> 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.25ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	No <u>** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members*</u> 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

	Vaccine	Primary Series	1 st Booster (Dose 3)	2 nd Booster (Dose 4)
<p>Ages 60 to 69</p> <p>Recommended to use Moderna unless a medical contraindication.</p>	Pfizer Adult/Adolescent formulation	2 dose series 8 weeks (56 days) Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after second dose Dosage: 0.3 ml **Preferentially recommended to use Moderna	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml **Preferentially recommended to use Moderna
	Moderna	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5ml	Yes 3 months (84 days) after second dose Dosage: 0.25ml	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.25ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

Ages 70+ Recommended to use Moderna unless a medical contraindication.	Pfizer Adult/Adolescent formulation	2 dose series 8 weeks (56 days) Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after second dose Dosage: 0.3 ml **Preferentially recommended to use Moderna	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml **Preferentially recommended to use Moderna
	Moderna	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

Anyone completing a primary series who has received partial series of Az or has received non-Health Canada approved vaccines can follow Table-1 above.

Those who received a series of Viral Vector (2-AZ or 1 dose of J&J) or Novavax can have a booster of mRNA following the Table-1 above.

THOSE WHO ARE SEVERELY OR MODERATELY IMMUNOCOMPROMISED:

- Receiving dialysis (hemodialysis or peritoneal dialysis)
- Receiving active treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome
- Individuals receiving active treatment with the specific immunosuppressive therapies (refer to list in directive)

(Table-2) Eligible by Age and Immunocompromised for Moderna/Pfizer Vaccines

	Vaccine	Primary Series	1 st Booster (Dose 4)	2 nd Booster (Dose 5)
Ages 5 to 11 Severely or Moderately Immunocompromised	Pfizer pediatric formulation (orange vial)	3 dose series 8 weeks (56 days) between doses Minimum 21 days Dosage: 0.2 ml	No	No

	Vaccine	Primary Series	1 st Booster (Dose 4)	2 nd Booster (Dose 5)
Ages 12 to 17 Severely or Moderately Immunocompromised	Pfizer Adult/Adolescent formulation (purple vial)	3 dose series 8 weeks (56 days) between doses Minimum 19 days Dosage: 0.3 ml	Yes 6 months (168 days) after third dose Dosage: 0.3 ml	No

	Vaccine	Primary Series	1 st Booster (Dose 4)	2 nd Booster (Dose 5)
Ages 18 to 28 Severely or Moderately Immunocompromised	Pfizer Adult/Adolescent formulation (purple vial)	3 dose series 8 weeks (56 days) between doses Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after third dose Dosage: 0.3 ml	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members* 5 months (140 days) after fourth dose Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml
	Moderna **only to be used when supply of Pfizer is depleted or with client informed consent	3 dose series 8 weeks (56 days) between doses Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after third dose Dosage: 0.5 ml	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members* 5 months (140 days) after fourth dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members* 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

	Vaccine	Primary Series	1 st Booster (Dose 4)	2 nd Booster (Dose 5)
Ages 30 to 59 Severely or Moderately Immunocompromised	Pfizer Adult/Adolescent formulation	3 dose series 8 weeks (56 days) between doses Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after third dose Dosage: 0.3 ml <small>**Preferentially recommended to use Moderna</small>	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members* 5 months (140 days) after fourth dose Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml <small>**Preferentially recommended to use Moderna</small>
	Moderna	3 dose series 8 weeks (56 days) between doses Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after third dose Dosage: 0.5 ml	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members* 5 months (140 days) after fourth dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	No ** Yes if 18+ First Nations, Inuit, Metis and their non-Indigenous household members* 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

Ages 60 to 69 Severely or Moderately Immunocompromised Recommended to use Moderna unless a medical contraindication.	Vaccine	Primary Series	1 st Booster (Dose 4)	2 nd Booster (Dose 5)
	Pfizer Adult/Adolescent formulation	3 dose series 8 weeks (56 days) between doses Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after third dose Dosage: 0.3 ml <small>**Preferentially recommended to use Moderna</small>	Yes 5 months (140 days) after fourth dose *Minimum interval of 3 months (84 days) with informed consent Dosage: 0.3 ml <small>**Preferentially recommended to use Moderna</small>
	Moderna	3 dose series 8 weeks (56 days) between doses Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after third dose Dosage: 0.5 ml	Yes 5 months (140 days) after fourth dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

Ages 70+ Severely or Moderately Immunocompromised Recommended to use Moderna unless a medical contraindication.	Vaccine	Primary Series	1 st Booster (Dose 4)	2 nd Booster (Dose 5)
	Pfizer Adult/Adolescent formulation	3 dose series 8 weeks (56 days) between doses Minimum 19 days with informed consent Dosage: 0.3 ml	Yes 3 months (84 days) after third dose Dosage: 0.3 ml <small>**Preferentially recommended to use Moderna</small>	Yes 5 months (140 days) after fourth dose *Minimum 3 months (84 days) with informed consent Dosage: 0.3 ml <small>**Preferentially recommended to use Moderna</small>
	Moderna	3 dose series 8 weeks (56 days) between doses Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after third dose Dosage: 0.5 ml	Yes 5 months (140 days) after fourth dose Minimum 3 months (84 days) (with informed consent) Dosage: 0.5 ml
	Novavax	2 dose series 8 weeks (56 days) Minimum 21 days with informed consent Dosage: 0.5 ml	Yes 3 months (84 days) after second dose Dosage: 0.5 ml	Yes 5 months (140 days) after third dose Minimum 3 months (84 days) with informed consent Dosage: 0.5 ml

Anyone completing a primary series who has received partial series of Az or has received non-Health Canada approved vaccines can follow Table-2 above.

Those who received a series of Viral Vector (2-AZ or 1 dose of J&J) or Novavax can have a booster of mRNA at 3 months following Table-2 above.

Severely or Moderately Immunocompromised: Re-immunization Recommendation

Those who have received a hematopoietic stem cell transplants (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy should be re-vaccinated with a new COVID-19 vaccine primary series post-transplantation due to the loss of immunity following therapy or transplant.

For additional information, please refer to the updated [COVID-19 Vaccination Recommendations for Special Populations](#) document.

Five Dose Schedule for High-Risk – LTCH/Rhome/Elder Care Lodge or Other Seniors Congregate Living Setting

(Table-5) Eligible by Living Setting

Resident of a LTCH, Rhome, Elder Care Lodge or Other Seniors Congregate Living setting (regardless of age)	Dose 1	Dose 2 8 weeks after dose one	Dose 3 3 months (84 days) after second dose	Dose 4 3 months (84 days) after third dose	Dose 5 3 months (84 days) after fourth dose
			MOHs have approved up to one week before 3 months (84 days) as acceptable to give without consult needed		
*Moderna preferentially recommended for seniors' d/t ↑ immune response	Pfizer 0.3 ml	Pfizer 0.3 ml	Pfizer 0.3 ml	Pfizer 0.3 ml	Pfizer 0.3ml
	Moderna 0.5 ml	Moderna 0.5 ml	Moderna 0.5 ml	Moderna 0.5 ml	Moderna 0.5 ml

Those living in other congregate settings (i.e. group homes, shelters) should follow primary and booster doses as per table on first page for their age.

Post Infection Immunization Guidance

Individuals 5 to 11 years of age - It is recommended that the child receive the COVID-19 vaccine, even after previous infection with SARS-CoV-2. If child had COVID-19 before receiving first or second COVID-19 vaccine dose, it is suggested they receive their first/second dose 8 weeks after symptom onset or positive test (if asymptomatic). If your child is moderately or severely immunocompromised, it is suggested that COVID-19 vaccine be offered 4-8 weeks after symptom onset of positive case. If child has a history of MIS-C, it is suggested to wait at least 90 days after recovery or symptom onset of MIS-C (whichever is longer).

Individuals who experienced SARS-CoV-2 infection before starting or completing their primary COVID-19 vaccine series are suggested to receive their next dose 8 weeks after symptom onset or positive test (if asymptomatic).

Individuals 12 years of age and older, infected with COVID-19 after their primary series but before their booster dose, are suggested to receive their booster dose three months after symptom onset or positive test (if asymptomatic) and provided it is at least 6 months from completing the primary series. As per NACI, emerging evidence indicates that a longer interval between SARS-CoV-2 infection and vaccination is associated with improved antibody responses to COVID-19 vaccines.

*A previous infection with SARS-CoV-2 is defined as a COVID-19 case confirmed by a molecular (e.g., PCR) or rapid antigen test, or [symptomatic](#) AND a household contact of a confirmed COVID-19 case.

These suggested intervals are based on immunological principles and expert opinion, and may change as evidence on COVID-19, variants of concern (VOCs), and COVID-19 vaccines emerge. When considering whether or not to administer vaccine doses following the suggested intervals outlined, biological and social risk factors for exposure (e.g., local epidemiology, circulation of VOCs, living settings) and severe disease should also be taken into account. These intervals are a guide and clinical discretion is advised.